financetom
Business
financetom
/
Business
/
BYD tops Singapore vehicle sales so far this year, replacing Toyota
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BYD tops Singapore vehicle sales so far this year, replacing Toyota
May 26, 2025 7:25 AM

SINGAPORE (Reuters) -China's BYD became the most popular vehicle brand in Singapore so far this year, outselling Toyota ( TM ) for the first time, government data showed, as the fast-growing electric vehicle maker steps up efforts to boost overseas sales.

In the first four months of 2025, BYD sold 3,002 cars, or 20% of total vehicle sales in Singapore. Toyota ( TM ) and BYD's main EV rival Tesla sold 2,050 and 535 units each during the same period.

Toyota ( TM ) used to hold the crown in the wealthy Asian financial hub where the population of cars is kept steady by an expensive certificate system, selling 7,876 cars in 2024, versus BYD's 6,191 sales.

BYD's robust sales growth in Singapore underscores its efforts to focus on overseas markets amid bruising price competition in China. Reuters reported this month that China's No.1 automaker aims to sell half of its vehicles outside the Chinese market by 2030, a massive increase that would make it a rival to the world's largest automakers.

BYD entered Singapore's consumer car market in 2022, more than a year later than Tesla, but has since reported much stronger sales growth.

In 2023, for example, the Chinese firm's sales almost doubled to 1,416, while Tesla sales rose just 7% to 941 units during the same period.

Singapore is one of the most expensive cities in the world to own a car, where a compact BYD Atto 3 SUV costs at least S$165,888 ($127,500) and the rival Toyota Corolla Altis is priced at around S$170,888.

BYD has already had early success in Southeast Asia, claiming Thailand as its biggest overseas market as it plans to expand in Europe and Latin America.

($1 = 1.3008 Singapore dollars)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved